NCT05698238View on ClinicalTrials.gov

Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

Clear Cell Renal Cell Carcinoma MetastaticTNBC - Triple-Negative Breast CancerHead and Neck CancerNon-small-cell Lung CarcinomaMesothelioma, Malignant

Interventions

DRUG

CA9hu-1

Humanized monoclonal antibody to human carbonic anhydrase IX

All Listed Sponsors

lead

Mabpro, a.s.

INDUSTRY

NCT05698238 - Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter